A renoprotective effect of treatment with canagliflozin has also been shown in patients with T2DM and chronic kidney disease (CKD, mean eGFR 56.2 mL/min, median urinary albumin [mg] to creatinine [g] ratio [ACR] 927) in the CREDENCE (Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation) trial [43], and a more recent meta-analysis including this trial has suggested that treatment with SGLT2 inhibitors improves CV outcome irrespective of established CV history or kidney function among patients with T2DM [44]. The gene discussed is SLC5A2; the disease is diabetes mellitus.